Infectious Disease

In every population that encounters an infectious organism, a few individuals prove to be resilient—unfazed by that pathogen because they are either resistant to it (their immune systems keep the pathogen from multiplying to dangerous levels) or tolerant (they don’t get as sick as they otherwise might despite carrying high pathogen loads). Conventional disease treatments such as antibiotics have almost exclusively sought to emulate natural resistance by keeping patients’ pathogen levels as low as possible.

The chikungunya virus (CHIKV) is quickly spreading through the Western Hemisphere; as of May 15, 2015, the Pan-American Health Organization (PAHO) had tallied close to 1.4 million suspected cases and more than 33,000 confirmed cases since the virus’ first appearance in the Americas in December 2013. Spread by mosquitoes, chikungunya is rarely fatal but can cause debilitating joint and muscle pain, fever, nausea, fatigue and rash, and poses a growing public health and national security risk. Governments and health organizations could take more effective proactive steps to limit the spread of CHIKV if they had accurate forecasts of where and when it would appear. But such predictions for CHIKV and other emerging infectious diseases remain beyond the reach of current modeling capabilities.

The ThoR program seeks to discover biological mechanisms of host tolerance to catalyze the development of novel host-based interventions against emerging pathogens and potential biological threat agents.